Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693011 · ClinicalTrials.gov registry record · NA
Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)
A NA study of Cerebral Aneurysms, sponsored by Cerus Endovascular.
- Recruiting
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 4
- Study locations
NCT06693011 is a NA study of Cerebral Aneurysms that is actively recruiting participants, run by Cerus Endovascular. The registered enrollment target is 250 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT06693011, a NA study of Cerebral Aneurysms, is actively recruiting participants, sponsored by Cerus Endovascular.
- RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to collect additional data to demonstrate if the Contour Neurovascular System (CNS) is a safe and effective treatment of wide-necked, saccular, intracranial aneurysms. Participants will: Undergo treatment with the Contour Neurovascular System Complete follow-up visits at 1month, 12months, and 24 months, following their procedure Report any adverse events to their study team
Conditions Studied
Interventions
- DEVICE Contour Neurovascular System Treatment Attempt
Study Locations (4)
New York
- University at Buffalo Neurosurgery - Buffalo
- Stony Brook University - Stony Brook
Pennsylvania
- University of Pennsylvania - Philadelphia
Washington
- Swedish Neuroscience Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2030-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06693011
The ClinicalTrials.gov registry entry for NCT06693011 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerus Endovascular, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cerebral Aneurysms appearing as the primary indexed condition, and to 1 intervention - of which Contour Neurovascular System Treatment Attempt is the first listed.
NCT06693011 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New York, Pennsylvania, Washington.
Frequently Asked Questions
What is clinical trial NCT06693011 about?
NCT06693011 is a clinical study titled "Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)". The goal of this clinical trial is to collect additional data to demonstrate if the Contour Neurovascular System (CNS) is a safe and effective treatment of wide-necked, saccular, intracranial aneurysms. Participants will: Undergo treatment with the Contour Neurovascular System Complete follow-up v...
What is the current status of trial NCT06693011?
This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2025-06-10. Estimated completion is 2030-01.
What conditions does trial NCT06693011 study?
This clinical trial studies the following conditions: Cerebral Aneurysms.
What interventions are being tested in trial NCT06693011?
The interventions under investigation include: Contour Neurovascular System Treatment Attempt (DEVICE).
Who is sponsoring clinical trial NCT06693011?
This trial is sponsored by Cerus Endovascular, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693011 being conducted?
This trial has 4 study locations across New York, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Aneurysms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.